Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor

Br J Pharmacol. 2007 Sep;152(2):207-15. doi: 10.1038/sj.bjp.0707359. Epub 2007 Jul 2.

Abstract

Background and purpose: Angiogenesis is a crucial step in tumour growth and metastasis. Ginsenoside-Rb1 (Rb1), the major active constituent of ginseng, potently inhibits angiogenesis in vivo and in vitro. However, the underlying mechanism remains unknown. We hypothesized that the potent anti-angiogenic protein, pigment epithelium-derived factor (PEDF), is involved in regulating the anti-angiogenic effects of Rb1.

Experimental approaches: Rb1-induced PEDF was determined by real-time PCR and western blot analysis. The anti-angiogenic effects of Rb1 were demonstrated using endothelial cell tube formation assay. Competitive ligand-binding and reporter gene assays were employed to indicate the interaction between Rb1 and the oestrogen receptor (ER).

Key results: Rb1 significantly increased the transcription, protein expression and secretion of PEDF. Targeted inhibition of PEDF completely prevented Rb1-induced inhibition of endothelial tube formation, suggesting that the anti-angiogenic effect of Rb1 was PEDF specific. Interestingly, the activation of PEDF occurred via a genomic pathway of ERbeta. Competitive ligand-binding assays indicated that Rb1 is a specific agonist of ERbeta, but not ERalpha. Rb1 effectively recruited transcriptional activators and activated an oestrogen-responsive reporter gene. Furthermore, Rb1-mediated PEDF activation and the subsequent inhibition of tube formation were blocked by the ER antagonist ICI 182,780 or transfection of ERbeta siRNA, indicating ERbeta dependence.

Conclusions and implications: Here we show for the first time that the Rb1 suppressed the formation of endothelial tube-like structures through modulation of PEDF via ERbeta. These findings demonstrate a novel mechanism of the action of this ginsenoside that may have value in anti-cancer and anti-angiogenesis therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Cell Line
  • Endothelial Cells / drug effects*
  • Endothelial Cells / physiology
  • Estradiol / analogs & derivatives
  • Estradiol / pharmacology
  • Estrogen Antagonists / pharmacology
  • Estrogen Receptor beta / agonists*
  • Estrogen Receptor beta / antagonists & inhibitors
  • Estrogen Receptor beta / genetics
  • Estrogen Receptor beta / metabolism
  • Eye Proteins / metabolism*
  • Fulvestrant
  • Ginsenosides / pharmacology*
  • Humans
  • Nerve Growth Factors / metabolism*
  • RNA, Messenger / metabolism
  • Serpins / metabolism*

Substances

  • Angiogenesis Inhibitors
  • Estrogen Antagonists
  • Estrogen Receptor beta
  • Eye Proteins
  • Ginsenosides
  • Nerve Growth Factors
  • RNA, Messenger
  • Serpins
  • pigment epithelium-derived factor
  • Fulvestrant
  • Estradiol
  • ginsenoside Rb1